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Senescence: novel insight into 
DLX3 mutations leading to 
enhanced bone formation in  
Tricho-Dento-Osseous syndrome
Na Zhao1, Dong Han1, Haochen Liu1, Yue Li1, Sing-Wai Wong1,2, Zhengyi Cao3, Jian Xu4, 
Xiaowei Zhang3, Tao Cai5,6, Yixiang Wang7 & Hailan Feng1
The homeodomain transcription factor distal-less homeobox 3 gene (DLX3) is required for hair, 
tooth and skeletal development. DLX3 mutations have been found to be responsible for Tricho-
Dento-Osseous (TDO) syndrome, characterized by kinky hair, thin-pitted enamel and increased bone 
density. Here we show that the DLX3 mutation (c.533 A>G; Q178R) attenuates osteogenic potential 
and senescence of bone mesenchymal stem cells (BMSCs) isolated from a TDO patient, providing a 
molecular explanation for abnormal increased bone density. Both DLX3 mutations (c.533 A>G and 
c.571_574delGGGG) delayed cellular senescence when they were introduced into pre-osteoblastic cells 
MC3T3-E1. Furthermore, the attenuated skeletal aging and bone loss in DLX3 (Q178R) transgenic mice 
not only reconfirmed that DLX3 mutation (Q178R) delayed cellular senescence, but also prevented 
aging-mediated bone loss. Taken together, these results indicate that DLX3 mutations act as a loss 
of function in senescence. The delayed senescence of BMSCs leads to increased bone formation by 
compensating decreased osteogenic potentials with more generations and extended functional 
lifespan. Our findings in the rare human genetic disease unravel a novel mechanism of DLX3 involving 
the senescence regulation of bone formation.
Distal-less homeobox 3 (DLX3), mapped to 17q21.33, is a member of the distal-less vertebrate family (DLX1-6), 
which has a crucial function in the development and differentiation process1,2. Inactivated Dlx3 in mice leads to 
transcription factor placental failure, suggesting Dlx3 is indispensable in placental development3. DLX3, regarded 
as a homeodomain transcription factor in vertebrate, is required for hair follicle differentiation and cycling pro-
grams, for tooth morphogenesis, and for skeletal formation and development1,4–6. Mutations of DLX3 are closely 
related to Tricho-Dento-Osseous syndrome (TDO; OMIM 190320), which is a disorder with autosomal domi-
nant inheritance mainly characterized by kinky hair, thin-pitted enamel (with remarkable attrition), dentin hypo-
plasia, and taurodontism as well as increased thickness and density of cranial and mandibular bones. To date, only 
six mutations in the DLX3 gene have been identified within minority family groups7–10 (Supplementary Fig. S1). 
Among them, the most common mutation in DLX3 is a frameshift mutation (c.571_574delGGGG; G191RfsX66), 
resulting in recoding and truncating the C-terminal transactivating domain of the DLX3 protein7. However, the 
de novo missense mutation (c.533 A> G; Q178R), previously reported in our department, was found in the home-
odomain of the encoded protein11.
The patients with the TDO syndrome, showing a marked increased bone mineral density (BMD) in endo-
chondral and intramembranous bones, imply that DLX3 exerts an essential role in bone formation. It has been 
identified that DLX3 is not only detected in osteoprogenitor cells, osteoblasts and osteocytes in vitro, but also is 
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expressed in both developing and postnatal bones in vivo12–14. Studies have strongly suggested the importance 
of Dlx3 in bone by directly regulating bone differentiation determinants, such as osteocalcin (Ocn), Runx2 and 
osteoactivin15–17. Notably, the accrual of bone mass and density is observed in transgenic mice with Dlx3 ablation 
in osteogenic lineage cells, suggesting that Dlx3 has a negative effect on osteogenesis14.
Aging brings significant changes to skeletal system with gradually bone loss, as well as a shift in tissue microen-
viroment with cellular senescence in bone marrow, like osteoporosis18,19. The replicative bone marrow-derived 
mesenchymal stem cells (BMSCs) senescence encompasses a progressive loss of proliferation ability and a 
declining osteodifferentiation potential20,21. Misexpression of Dlx3 in the basal proliferative layer of epidermis 
of transgenic mice induces cell cycle arrest and leads to premature terminal differentiation22. In normal human 
epidermal keratinocytes, exogenous DLX3 promotes cell cycle arrest by activating tumor suppressor gene p53 
and cyclin-dependent kinase inhibitor p21, which play critical roles in cell cycle and senescence regulation23. 
Collectively, these data suggest a possible role for DLX3 in senescence during epidermis proliferation and differ-
entiation. However, whether DLX3 function as a modulator of cellular senescence involving bone formation has 
not been experimentally investigated.
To address the effect of DLX3 mutations on senescence during bone formation, we firstly isolated naïve 
BMSCs from a TDO patient with DLX3 mutation (c.533 A> G; Q178R). Interestingly, an attenuated osteoblastic 
activity accompanying with a delayed cellular senescence was observed in the BMSCs harboring the c.533 A> G 
mutation when compared with gender- and age-matched healthy BMSCs. This finding was further verified and 
was mechanistically studied by transfecting plasmids of the wild type DLX3, the mutant DLX3 (c.533 A> G) and 
the truncated DLX3 (c.571_574delGGGG) into pre-osteoblastic MC3T3-E1 cells. Consistently, the attenuated 
bone loss and aging in the aged transgenic mice with DLX3 mutation (c.533 A> G) suggest a regulatory role of 
DLX3 in the context of senescence during bone formation.
Results
Isolation of BMSCs from the patient with TDO. The 27-yr-old female patient with typical TDO features 
was enrolled in this study (Supplementary Fig. S2A,B and C)11. Specially, thickened cortical and abnormally 
increased trabecular bone density of mandibular was clearly observed in the patient’s panoramic radiograph. 
The cephalometric radiograph of the patient showed a bossed frontal bone, a square jaw, increased bone density 
and thickness in parietal and calvaria bones, with a lack of pneumatization of the mastoids. Mandibular bone 
specimens of the patient were collected during implant surgery (Supplementary Fig. S3A). Bone marrow derived 
stem cells were isolated from the specimen (named as TDO-BMSCs) and reached 80% confluence after 14 days 
culture (Supplementary Fig. S3B). The missense mutation of DLX3 (c.533 A> G; Q178R) was confirmed by Sanger 
sequencing in the blood sample as well as in the BMSCs of the patient (Supplementary Fig. S2D). Further, BMSCs 
isolated from three gender- and age-matched normal donors as controls (named as CON-BMSCs). The flow 
cytometry assay, which showed that both TDO- and CON-BMSCs were negative for the hematopoietic markers 
CD34 and CD45, and positive for the mesenchymal stem cell-associated markers CD73, CD90, and CD106, indi-
cated that DLX3 mutation did not affect expression of stem cell markers (Supplementary Fig. S3C).
TDO-BMSCs exhibit weaker osteogenic potential than CON-BMSCs. Due to the increased bone 
density in TDO patient, we firstly explored the inter-group differences on osteogenic potential. Under osteoin-
ductive condition, the third passage of TDO-BMSCs differentiated into osteoblasts but showed lower levels of 
alkaline phosphatase (ALP) activity as assessed by ALP staining and ALP activity assays on day 3, 7, and 14 
compared with CON-BMSCs (Fig. 1A,C). After osteoinduction for 14 and 21 days, Alizarin red staining (ARS) 
of calcium deposition with less staining intensity in TDO-BMSCs further confirmed these results (Fig. 1B,D). 
Western blot analysis indicated that the protein levels of RUNX2 and BSP were lower in TDO-BMSCs at 14 days 
post-osteoinduction (Fig. 1E). Meanwhile, by real-time PCR, the mRNA levels of RUNX2, ALP, Collagen I, BSP, 
and OCN were decreased in TDO-BMSCs on day 7 and 14 after osteoinduction, whereas the opposite effects were 
observed in CON-BMSCs (Fig. 1F). In addition, both real-time PCR and western blot analysis revealed lower 
levels of RANKL/OPG in TDO- relative to CON-BMSCs (Fig. 1E,F). Of note, DLX3 expression in TDO-BMSCs 
was half of that in normal controls (Supplementary Fig. S4).
TDO-BMSCs exhibit slower senescence rate than CON-BMSCs. Since the panoramic radiograph 
indicated that the mandibular was heavily mineralized, decreased osteogenic potential apparently could not 
account for the phenotype of TDO. After literature reviewing, an important consideration is emphasized that 
bone formation is not only dependent on the osteogenic activity of individual osteoblast but also on the sta-
tus of cellular senescence18,19,24. Of note, the classic senescence cell morphology, which was enlarged, flattened 
cellular morphology and a decline replicate proliferation, was observed in gender-, age- and passage-matched 
CON-BMSCs. Whereas, TDO-BMSCs, cultured for the same condition, showed relative younger state, with regu-
larly long spindle-shaped fibroblast-like morphology (Supplementary Fig. S5). Thus, we examined whether DLX3 
mutation intrinsically affected BMSCs senescence with further research.
Senescence-associated β -galactosidase (SA-β -gal), defined as a β -galactosidase activity detectable at pH 
6.0, has been used as a common marker for aged cells as it has been demonstrated to increase with aging of 
various cells both in vitro and in vivo25,26. The number of SA-β -gal+ staining cells 38% in TDO-BMSCs and 
55% in CON-BMSCs suggested that BMSCs with DLX3 mutation remained a younger status while the normal 
BMSCs entered a premature senescence (Fig. 2A,B). Consistently, GLB1 expression, the gene encoding lysosomal 
β -galactosidase27, was measured by flow cytometry and showed a lower level in TDO-BMSCs (Fig. 2C).
Previous studies have identified that accelerated telomere shortening is observed in senescence cells28. Relative 
telomere length (expressed as relative ratio of telomere to single-copy gene (36B4) [relative T/S ratio]) and abso-
lute telomere length (expressed kb/diploid genome) at passage 5 and 9 was measured by quantitative real-time 
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PCR. It has been acknowledged that the decrease in the relative T/S ratio positively correlates with telomere short-
ening29,30. The results showed that the relative T/S ratio was higher in TDO-BMSCs (Fig. 2D). Moreover, absolute 
telomere length results further confirmed that TDO-BMSCs had longer telomeres (Fig. 2E).
p16INK4a, p15INK4b, and p21, encoded by CDKN2A gene, CDKN2B gene and CDKN1A respectively, together 
with tumor suppressive p53 transcription factor, were considered core elements of signaling pathways involved 
in cell senescence for their activation inducing cells into irreversible cell cycle arrest31–33. On the other hand, 
OCT4 and NANOG were stem cell specific transcription factors for maintaining pluripotency of stem cells during 
development34,35. The real-time PCR results showed that aging-related genes (p16INK4a, p15INK4b, and p53) were 
down-regulated and stem cell-associated genes (OCT4 and NANOG) were up-regulated in the passages 6, 7, and 
8 in TDO-BMSCs (Fig. 2F). Correspondingly, western blot analysis also exhibited that p16INK4a protein expres-
sion was significantly reduced, while OCT4 expression was clearly increased in TDO-BMSCs (Fig. 2G). These 
results not only confirm that DLX3 mutation prevents the premature senescence of BMSCs but also indicates 
that DLX3 mutation stabilizes the pluripotency of BMSCs. Prolonged expression of stemness-related genes allow 
TDO-BMSCs to produce more “stem”-like osteogenic cells, to generate more daughter cells, and to extend the 
functional lifespan of osteoblastic cells to perform bone remodeling.
Figure 1. TDO-BMSCs exhibit weaker osteogenic potential than CON-BMSCs. TDO- and CON-BMSCs 
at passage 3 were cultured under osteoinduction medium. (A) ALP staining assay on days 3, 7, and 14 after 
osteoinduction. (B) Alizarin red staining assay at 14 and 21 days post-osteoinduction. (C) ALP activity assay 
on days 3, 7, and 14 after osteoinduction. (D) Quantification of alizarin red staining on days 14 and 21 post-
osteoinduction. (E) Western blots of RUNX2, BSP, RANKL, OPG, and β -actin protein 14 days after osteogenic 
stimulation. (F) Osteogenesis-related genes (RUNX2, ALP, COLLAGEN I, BSP, OCN, RANKL and OPG) mRNA 
expression after osteoinduction. GAPDH served as an internal control. Data were presented as the mean ± S.D. 
of 3 independent experiments. *p < 0.05; **p < 0.01.
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Overexpression of WT-DLX3, MT-DLX3 and TR-DLX3 in MC3T3-E1 cells. To abrogate background 
difference generated by different donors’ cells and to further identify whether the novel mutation is a gain- or 
loss- of function, we constructed plasmids of wild type DLX3, mutant DLX3 (c.533 A> G) and mutant DLX3 
(c.571_574delGGGG), and transfected into osteoprogenitor cells MC3T3-E1 to investigate their function on oste-
ogenic differentiation and aging in vitro. Of note, the mutant DLX3 (c.571_574delGGGG) was used to confirm 
the effect of DLX3 mutation on osteogenic potential and senescence.
The recombinant plasmids in empty vector pEGFP-C1, carrying wild type DLX3 and mutant DLX3 
(c.533 A> G) and (c.571_574delGGGG) expression cassette were transfected into pre-osteoblastic cell line 
MC3T3-E1 and named as WT-DLX3, MT-DLX3 and TR-DLX3, respectively. MC3T3-E1 cells transfected with 
pEGFP-C1 empty vector (named as EGFP-EV) serves as control. The green fluorescence was detected under 
fluorescent microscope at 48 h post-transfection, and the results showed that transfection efficiency was over 
30% (Supplementary Fig. S7). EGFP expression tagged to WT-DLX3, MT-DLX3 and TR-DLX3 was detected in 
nucleus, whereas EGFP expression in empty pEGFP-C1 was in cytoplasm, suggesting that whether DLX3 mis-
sense mutation (c.533 A> G) or DLX3 truncation mutation (c.571_574delGGGG) could enter into nucleus, like 
wild type DLX3 (Fig. 3A). In addition, both real-time PCR analysis and western blot analysis showed that the 
expression of DLX3 was substantially increased in WT-DLX3, MT-DLX3 and TR-DLX3 cells (Fig. 3B,C).
Previous study have shown that DLX3 acted as a molecular switch that regulated RUNX2 expression through-
out bone formation, we here tested the ability of mutant DLX3 to bind RUNX2 promoter to determine whether 
deceased osteogenic potential associated with TDO-BMSCs were directly due to DLX3 mutation. The electro-
phoretic mobility shift (EMSA) experiments (Fig. 3D) showed that endogenous DLX3 could bind to the specific 
Figure 2. TDO-BMSCs exhibit slower senescence rate than CON-BMSCs. (A) Representative images of 
cells assayed for SA-β -gal activity (blue) (scale bar, 100 μ m). (B) Percentages of SA-β -gal+ cells/total cells from 
experiments as in panel (A) β -gal activity normalized to total cells. (C) Flow cytometry of the percentage 
of GLB1 expression compared with isotype controls. (D) Relative telomere length expressed as relative T/S 
ratio measured by quantitative real-time PCR analysis showing remarkably longer telomeres of TDO-BMSCs 
at passage 5 and 9. (E) Absolute telomere length expressed kb/diploid genome determined by qPCR also 
displaying longer telomeres of TDO-BMSCs at passage 5 and 9. (F) Real-time PCR for p16INK4a, p15INK4b, p53, 
OCT4, and NANOG in TDO- and CON-BMSCs at the passages 6, 7, and 8. (G) Western blots of p16INK4a, 
OCT4, and NANOG protein levels; GAPDH served as an internal control. Data were presented as the 
mean ± S.D. of 3 independent experiments. *p < 0.05; **p < 0.01.
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oligonucleotide probe. WT-DLX3, MT-DLX3 and TR-DLX3 were also able to bind the probe. The DLX3 EMSA 
signal was specific, as determined by competition with a 100-fold excess of unlabeled probe (wild-type [WT] 
probe), but not by an unlabeled mutant probe (MT probe) bearing point mutations in the high-affinity site. In 
addition, the stronger band in the lanes with the transfected WT-DLX3, MT-DLX3 and TR-DLX3 could be super-
shifted with anti-GFP, confirming that WT-DLX3, MT-DLX3 and TR-DLX3 do specifically bind the high-affinity 
site probe.
WT-DLX3 and TR-DLX3 increase while MT-DLX3 decreases cellular osteogenesis in MC3T3-E1 
cells. Since the mutations in DLX3 did not change the DNA bind activity to RUNX2 promoter, we examined 
whether DLX3 mutations could affect osteogenic potential of MC3T3-E1 cells. After osteoinduction for 72 h, 
osteoblastic markers Runx2, Alp, Bsp, and Ocn mRNA expression detected by real-time PCR at mRNA level 
Figure 3. Cellular localization, DNA binding property to RUNX2 and overexpression of WT-DLX3, 
MT-DLX3 or TR-DLX3 in MC3T3-E1 cells. (A) Panels showing EGFP and EGFP-DLX3 fusion protein 
expression in MC3T3-E1 cells 48 h after transfection with pEGFP-C1, pWT-DLX3, pMT-DLX3 and pTR-DLX3. 
Differential interference contrast (DIC) images were acquired to visualize cell shape (a, d, g and j). Images of 
EGFP expression (b, e, h and k) were detected by fluorescent microscope. WT-DLX3, MT-DLX3 or TR-DLX3 
was located in nuclear while the EGFP was in cytoplasm, which was shown in the merged images (c, f, i and l).  
(B) DLX3 mRNA expression was highly enhanced in WT-DLX3, MT-DLX3 and TR-DLX3 compared with 
EGFP-EV after 48 h transfection by real-time PCR. (C) DLX3-GFP protein expression was detected by western 
blot analysis with anti-DLX3 (a) and anti-EGFP (b) antibodies after 48 h transfection. Only EGFP protein 
was detected in EGFP-EV samples. EGFP-DLX3 fusion protein was detected in WT-DLX3, MT-DLX3 and 
TR-DLX3 samples. Data were presented as the mean ± S.D. of 3 independent experiments. **p < 0.01; Scale 
bars = 100 μ m. (D) DLX3 occupies its affinity site in the RUNX2 promoter. EMSA assay was performed by 
using a biotin-labeled double-stranded probe (containing the DLX3 affinity site). Nuclear extracts (10 μ g) from 
HEK 293 T cells expressing GFP-WT-DLX3, GFP-MT-DLX3 or GFP-TR-DLX3 were used. The wild type probe 
(GCATTTTGTAATTTATTTCAAAGC) and the mutant probe (GCATTTTGTGGGTTATTTCAAAGC) were 
used as unlabeled competitors at a 100-fold excess. The presence of specific complexes, including supershifted 
GFP/DLX3 in the complexes, are indicated.
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(Fig. 4A) and by western blot analysis at protein level (Fig. 4B,C) were slightly increased in WT-DLX3 and sig-
nificantly increased in TR-DLX3, but remarkably decreased in MT-DLX3 when compared with EGFP-EV. ALP 
staining assay further confirmed these results by showing higher ALP activity in WT-DLX3 and TR-DLX3, lower 
in MT-DLX3 (Fig. 4D). These results suggest that different DLX3 mutations have different function on osteogene-
sis even though both of them could locate into nucleus and bind to RUNX2 promoter. Of note, real-time PCR and 
western blot analysis showed that BMP2 expression was lower in TDO-BMSCs and was decreased in MT-DLX3 
but increased in TR-DLX3 (Supplementary Fig. S8).
Figure 4. WT-DLX3 and TR-DLX3 increase while MT-DLX3 decreases cellular osteogenesis in MC3T3-E1 
cells. MC3T3-E1 cells were transfected with pEGFP-C1, pWT-DLX3, pMT-DLX3 and pTR-DLX3 respectively. 
After 24 h transfection, these cells were further cultured in osteoinduction medium for 72 h. Then, the cells 
were harvested and subjected to real-time PCR and western blot. (A) Osteogenesis-related genes (Runx2, Alp, 
Collagen I, Bsp, and Ocn) mRNA expression were determined by real-time PCR. GAPDH served as an internal 
control. (B) Protein expression of RUNX2, BSP, OCN, and GAPDH were detected by western blot. GAPDH 
served as loading control. (C) Quantification of protein expression related to GAPDH. (D) ALP staining 
assay after osteoinduction for 72 h was performed. Data were presented as the mean ± S.D. of 3 independent 
experiments. *p < 0.05; **p < 0.01.
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WT-DLX3 pushes while MT-DLX3 and TR-DLX3 delays cellular senescence in MC3T3-E1 
cells. Apparently, the inhibition effect of DLX3 mutation (Q178R) on osteogenic differentiation had been 
revalidated, we further examined its effect on senescence. After 72 h osteoinduction, aging-related markers 
p16INK4a and p15INK4b mRNA expression detected by real-time PCR (Fig. 5A) and p16INK4a and GLB1 protein 
expression examined by western blot (Fig. 5B,C) were significantly increased in WT-DLX3 but decreased in 
MT-DLX3 and TR-DLX3 when compared with EGFP-EV. Stemness markers Oct4 and Nanog mRNA expression 
detected by real-time PCR (Fig. 5A) were significantly decreased in WT-DLX3 but increased in MT-DLX3 and 
TR-DLX3 when compared with EGFP-EV.
Exogenous H2O2 has been used extensively as an inducer of oxidative stress in vitro aging models. 
Therefore, SA-β -gal staining and relative telomere length was performed in WT-DLX3, MT-DLX3 or TR-DLX3 
overexpression-MC3T3-E1 cells exposed to 100 μ M H2O2 for 96 h. The results showed that percentage of 
SA-β -gal-positive cells was significantly higher in WT-DLX3, but much lower in MT-DLX3 and TR-DLX3 
(Fig. 5D,E). Telomere length assay by quantitative real-time PCR (Fig. 5F) demonstrated that T/S ration was 
aggravated in MT-DLX3 and TR-DLX3, but reduced in WT-DLX3, when compared with EGFP-EV. H2O2 
Figure 5. WT-DLX3 pushes while MT-DLX3 and TR-DLX3 delay cellular senescence in MC3T3-E1 cells. 
MC3T3-E1 cells were transfected with pEGFP-C1, pWT-DLX3, pMT-DLX3 and pTR-DLX3 respectively, and 
were further cultured for 72 h under osteodifferentiation induction. Then, the cells were harvested and subjected 
to do real-time PCR and western blot. (A) Senescence-related genes (p16INK4a and p15INK4b) and stemness-
related genes (Oct4 and Nanog) mRNA expression were determined by real-time PCR. GAPDH served as an 
internal control. (B) p16INK4a, GLB1 and GAPDH protein expression were detected by western blot. GAPDH 
served as loading control. (C) Quantification of protein expression related to GAPDH. (D) SA-β -gal staining 
was performed in WT-DLX3, MT-DLX3 or TR-DLX3 overexpression-MC3T3-E1 cells exposed to 100 μ M H2O2 
for 96 h. Representative images of SA-β -gal-positive cells (blue) (scale bar, 100 μ m). (E) Percentages of SA-β -gal+ 
cells/total cells from experiments as in panel (D) β -gal activity normalized to total cells. (F) Relative telomere 
length expressed as relative T/S ratio measured by quantitative real-time PCR analysis. Data were presented as 
the mean ± S.D. of 3 independent experiments. **p < 0.01.
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exposure further confirmed the functional discrepancy between the DLX3 mutations and wild type DLX3. These 
verified that both DLX3 mutations had negative effect on senescence.
DLX3 (Q178R) prevents skeletal aging and bone loss in vivo. Since DLX3 mutation (Q178R) could 
increase bone formation by preventing cell senescence even though with decreased osteogenic potential in vitro, 
we further generated transgenic mice expressing DLX3 mutation (Q178R) (named as DLX3 (Q178R)-Tg mice) 
to examine whether this novel mutation could protect against natural aging-mediated bone loss or osteopenia 
in vivo. Western blot analysis of DLX3 (Q178R) transgene was highly expressed in femur and tibia bone of 
founder mice (Supplementary Fig. S9A). Micro-CT analysis revealed that there was a gradual loss of trabecular 
bone mass with advancing age from 8 to 18 months in wild type mice (named as WT mice) (Fig. 6A). Further 
quantitative analysis showed that the most dramatic trabecular bone loss occurred between 8 and 16 months of 
age and average bone mineral density (BMD) dropped 62%, while bone volume/total volume (BV/TV) dropped 
79%. However, the reduction was significantly less with DLX3 (Q178R)-Tg mice, with 43% in BMD and 65% 
in BV/TV respectively (Fig. 6B). Of note, we confirmed that DLX3 transgene mRNA in bone tissues was still 
expressed in aged DLX3 (Q178R)-Tg mice using RT-PCR although the levels of DLX3 mRNA declined over age 
(Supplementary Fig. S9B). We also examined that whether natural aging-associated p16INK4a activation was sup-
pressed by DLX3 mutation (Q178R). While immunostaining of p16INK4a expression revealed p16INK4a activities in 
the vicinity of trabecular bones of WT mice. And p16INK4a activities appeared less prevalent in DLX3 (Q178R)-Tg 
mice (Fig. 6D). Consistently, the western blot analysis showed that the expression of p16INK4a, p53 and p21 were 
markedly weaker in DLX3 (Q178R)-Tg mice compared with WT mice (Fig. 6E).
To examine if DLX3 mutation (Q178R) attenuates osteoblastic activity in a cell-autonomous manner, we iso-
lated BMSCs from femurs of DLX3 (Q178R)-Tg and WT mice. Primary BMSCs from DLX3 (Q178R)-Tg mice 
demonstrated reduced osteogenic potential, as evidenced by ALP staining and Alizarin Red staining (ARS), when 
cells were induced by osteogenic medium (Fig. 6C).
Discussion
Herein we demonstrate a distinct role for DLX3 as an essential regulator of two integral processes in bone forma-
tion: osteogenesis and senescence. And our studies provide a possible explanation for abnormal bone formation 
of TDO patients and transgenic mice with DLX3 mutation (Q178R). Owing to the inhibition of osteogenic poten-
tial found in BMSCs isolated from the TDO patient or transgenic mice, the phenotype of increased bone mineral 
density is attributed to delayed cellular senescence caused by DLX3 mutation (Q178R). Additionally, the delayed 
Figure 6. DLX3 (Q178R) attenuates skeletal aging and bone loss in vivo. (A and B) Micro-CT analysis: 3D 
trabecular reconstructions (A) Trabecular BMD (Tb. BMD), Trabecular bone volume ratio (Tb. BV/TV) (B) 
of distal femoral metaphysis regions from 8- and 16-months-old WT and DLX3 (Q178R)-Tg mice. (C) ALP 
staining and Alizarin red staining (ARS) of femur bone BMSCs from 8-months-old DLX3 (Q178R)-Tg vs WT 
mice, after osteogenic induction. (D) Immunostaining with p16INK4a surrounding the trabecular bones from 
8-months-old WT and DLX3 (Q178R)-Tg mice. Scale bars, 25 μ m. (E) Western blot of p16INK4a, p53 and p21 in 
tibia and femur of 8 months mice.
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skeletal aging and attenuated bone loss in DLX3 mutation (Q178R)-Tg suggest that DLX3 mutation is able to 
prevent aging-related bone loss. Mechanistically, the function studies of WT-DLX3, MT-DLX3 and TR-DLX3 in 
MC3T3-E1 extend our knowledge of DLX3 function in osteogenesis and senescence, as well as function alteration 
caused by DLX3 mutations.
Previous studies have proved that DLX3 is a key regulator of osteoblastogenesis. Yet, what’s the function of 
DLX3 in osteoblast differentiation? Most in vitro function studies have shown that DLX3 have the capability to 
directly regulate osteogenic markers such as OCN, RUNX2, and osteoactivin15–17. Overexpression of DLX3 in 
osteoprogenitors promotes osteogenic differentiation, while knockdown of DLX3 suppresses13,15. However, these 
results are challenged by the experiments in vivo. Both of transgenic mice Dlx3Prx1-cKO and Dlx3OCN-cKO models, 
conditional loss-of-function mutations of Dlx3 in mesenchymal cells and in osteogenic lineage cells respectively, 
present an increased bone mass accrual throughout the lifespan due to direct enhancement of osteoblast activity 
and up-regulation expression of osteogenic essential markers, including Runx2 and its downstream target Sp714. 
Undoubtedly, these results show that DLX3 is a negative regulator of bone mass accrual. Taken together, the 
studies above provide contrasting results and emphasize that DLX3 plays an implicated and sophisticated role in 
bone formation.
Given the fact that the bone homeostasis is an intricate process orchestrated by hundreds of factors, an inter-
esting concept that emerges is that DLX3 performs its role in osteogenesis by coordinating with other osteogenic 
differentiation essential factors and constituting a regulatory network to keep the maintenance of bone home-
ostasis36. Firstly, DLX3 gene belongs to a Dlx homeobox transcription factors family, which consists of three 
inverted and convergent clusters (Dlx1/2, Dlx3/4 and Dlx5/6), and have essential function in skeleton develop-
ment2,37,38. Dlx5 and Dlx6 deficient mice exhibits bone and ossification defects2,38. Increased levels of Dlx5 and 
Dlx6 are induced in transgenic mice with Dlx3 deletion in osteogenic cells and are considered as a contributor 
to increased bone mineral density in the mice14. Hassan et al. show that the selection association of Dlx5, Msx2 
and Dlx3 binding to the Runx2 and Ocn promoter occurs in different stages of osteoblast maturation process15,16. 
Secondly, transcriptome studies exhibit that in vivo Dlx3 inactivation in osteogenic cells affects a wide range of 
developmental signals including Wnt, TGF-β /BMP and Notch pathways14. Previous studies have already shown 
that BMP2 induces the osteogenic differentiation, and Dlx3 are rapidly induced in response to BMP2-mediated 
osteoblast differentiation. Hassan et al. prove a regulatory pathway from BMP2 to commitment to osteogen-
esis via Dlx3 regulation16. Furthermore, the mechanism of Dlx3 and BMP2 regulation each other with a feed-
back control is inspected in the osteogenic differentiation of dental follicle cells39. Of note, our study showed 
that BMP2 expression was lower in TDO-BMSCs and was decreased in MT-DLX3 but increased in TR-DLX3 
(Supplementary Fig. S8), suggesting that these two different DLX3 mutations act as different proteins in trig-
gering osteogenic differentiation regulatory network. Meanwhile, the different expression levels of BMP2 also 
explain the reason of inhibited osteogenic potential in MT-DLX3 and promoted in TR-DLX3. Thirdly, as the fatal 
member in bone homeostasis, osteoclast activity is a force to be reckoned with. The ration of receptor activator 
of NF-κ B ligand (RANKL) and osteoprotegerin (OPG) is considered a marker of bone metabolism balance40. 
Isaac et al. demonstrate that Dlx3 deletion in osteoblasts gives rise to high levels of OPG, consequently resulting 
a decreased RANKL/OPG ratio and down-regulated bone resorption, and finally contributing to bone formation 
augment14. The phenotypes of increased bone volume and trabecular BMD in transgenic TDO mice (a mutant 
DLX3 (571_574delGGGG) driven by 2.3 Col1A1 promoter) are owing to decreased osteoclast formation and 
activity caused by increased IFN-γ , because the mice lack of enhanced dynamic bone formation in vivo41. Our 
study showed that DLX3 mutation (Q178R) in BMSCs leaded to a decreased RANKL/OPG ratio, which indicates 
a regulation balance against bone resorption. These results are further supported by our previous studies which 
reveal that DLX3 mutation (Q178R) inhibits osteoclast differentiation in Raw 264.7 cells by up-regulating osteo-
clastogenesis inhibitor microRNA-124 expression42. From this point, the two different DLX3 mutations share the 
same negative effect on osteoclasts activity.
Our functional studies in MC3T3-E1 showed that wild type DLX3 overexpression in vitro promoted osteo-
genic differentiation, which is consistent with the studies in vitro but opposite to the studies in vivo. Based on the 
concept of regulatory network to maintain bone homeostasis, it is possible that the in vitro studies exhibit DLX3 
direct function due to the lack of regulatory network in vitro, whereas the in vivo studies demonstrate that other 
regulators concerning bone homeostasis in the network compensate or overcompensate the function alteration 
caused by DLX3 inactivation or mutations. This hypothesis is supported by the studies in the TDO transgenic 
mouse which demonstrated that the BMSCs isolated from these mice exhibit enhanced osteogenic potentials, but 
the dynamic bone formation is lacked in the mouse41. Of note, DLX3 expression in TDO-BMSCs was almost half 
of that in normal controls (Supplementary Fig. S4) and the TDO-BMSCs exhibited lower osteogenic potentials 
in vitro. Yet, increased bone density was observed in the TDO patient in vivo. These studies not only further testify 
the existence of regulatory network to keep bone homeostasis but also indicate that DLX3 mutation (Q178R) act 
as a loss of function in vitro. Furthermore, our DLX3 mutation (Q178R) transgenic mice studies reconfirm this 
concept by showing that BMSCs isolated from these mice exhibited decreased osteogenic potentials in vitro, but 
these mice demonstrated increased BMD and trabecular bone volume in vivo. Collectively, we are inclined to take 
DLX3 as a direct positive regulator in osteogenesis in vitro. As for the reason responsible for the conflicts, our 
studies offer the notion of senescence as the answer.
Our findings that delayed senescence in TDO-BMSCs remedied and enhanced the bone formation in TDO 
patient in spite of declined osteogenic potentials cast a novel insight of DLX3 function in bone formation. In 
Isaac’s study, compared with the same age of wild type mice, loss of function of Dlx3 in Dlx3OCN-cKO mice results 
in femur BMD decreasing at 2 weeks to 5 weeks, but increasing from 4 months to the whole lifespan when 
compared with age matched wild-type mice14. These results indicate that DLX3 plays an important role in bone 
formation when age is increased. Our immunohistochemical analysis demonstrated that osteoblasts senescence 
was delayed by DLX3 (Q178R) mutation, and our Micro-CT analysis revealed that this delayed senescence 
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attenuated aging-mediated bone loss in vivo. Overall, these experiments determine the role of DLX3 in senes-
cence. Mechanistically, the functional studies in MC3T3-E1 showed that wild type DLX3 resulted in cell prema-
ture senescence, whereas both DLX3 mutations prevented cellular senescence. These results imply that DLX3 
positively regulates cellular senescence and both DLX3 mutations show a loss of function. In Palazzo’s study, the 
luciferase and EMSA assays demonstrates that Dlx3 regulated p21 expression by directly binding to p21 promoter 
or by co-regulating with p5323. Of note, DLX3 expression was lower in TDO-BMSCs (Supplementary Fig. S4). 
Taken together, DLX3 is therefore a positive regulator in senescence and it might regulate senescence through 
p53/p21-regulted network.
In general, evidence has accumulated that DLX3 plays a pleiotropic role in several biological process to main-
tain bone homeostasis in normal bone, whereas, in TDO patients, this homeostasis is jeopardized by DLX3 muta-
tion through triggering different pathways in the regulatory network to rectify this mistake. In this TDO patient, 
DLX3 (Q178R) mutation results in lower levels of expression of RUNX2, OCN, ALP, BMP2, p16INK4a, p53, p21, 
and so on, decreases osteogenesis and senescence. Mice lacking p16INK4a demonstrate increased proliferation and 
reduced frequency of apoptotic events, as well as enhanced repopulation ability by raising expression of stem cell 
self-renewal genes31,43. p21 deletion rescues proliferation and improves the repopulation capacity and self-renewal 
of stem cells from mice with dysfunctional telomeres44. The repressive expression of senescence genes rejuvenate 
BMSCs to keep the “young” state for their ability to self-renewal, proliferate, resistance to apoptosis and differen-
tiate24,45,46, thereby more generations and longer lifespan of BMSCs compensate the decreased osteogenic differ-
entiation propensity and finally lead to increased bone density.
Nevertheless, herein we focus on the role of DLX3 mutation in senescence, even though it might not be the 
only reason for the increased bone formation. Its role highlights a concept that DLX3 regulates bone formation by 
preventing senescence, gives us a novel sight to view DLX3 function in bone formation. Furthermore, increasing 
bone-and age-related disorder, especially in the aging population, is becoming a major socioeconomic burden to 
society. The osteoporosis exhibits net bone loss on account of skeletal aging47. The application of BMSCs in bone 
repair and regeneration is limited because of its senescence causing a high rate of failure48. To tackle the challenge, 
novel insight into transcriptional programs bound up with bone formation and aging process are urgent to exca-
vate novel therapeutic targets in future clinical trials. Our research of DLX3 mutation protecting aging-related 
bone loss opens the possibility of its therapeutic potential in bone regeneration and bone loss disease.
Methods
Isolation and identification of BMSCs from the TDO patient and normal donors. A 26-year-old 
female with typical TDO features11 and gender- and age-matched normal donors (n = 3) participated in this 
study with informed consent. The study was approved by the Ethics Committee of Peking University School and 
Hospital of Stomatology. And the whole methods were carried out in accordance with the relevant guidelines, 
including any relevant details. BMSCs were isolated from alveolar bone of the involved patient (TDO-BMSCs) 
and healthy donors (CON-BMSCs) during implantation surgery as described below. Briefly, the bone tissue was 
rinsed in sterile phosphate-buffered saline (PBS), cut into 1 mm3 cubes, and digested in collagenase I (Invitrogen 
Life Technologies, Grand Island, NY, USA) and dispase II (Roche, Indianapolis, IN) for 1 h at 37 °C. Cells were 
collected by centrifugation at 200 × g and seeded in a 100-mm culture dish in alpha minimum essential medium 
(Alpha-MEM, Gibco, Paisley, Scotland, UK) supplemented with 10% fetal bovine serum (FBS) (Gibco) and peni-
cillin-streptomycin and L-glutamine. Following overnight culture at 37 °C in a humidified atmosphere of 5% CO2 
and 95% air, unattached cells were discarded when the medium was changed. Cells at passage 3 were analyzed for 
stem cell-associated markers by flow cytometry. Details were described in supplementary.
Generation of transgenic mice and experimental animals. All animal experiments were approved 
by the Peking University Animal Care and Use Committee. All methods were performed in accordance with the 
relevant guidelines and regulations. Human DLX3 mutation (Q178R) gene flanked by the mouse cytokeratin 14 
promoter was subcloned into plasmid pGL647. The fragments of the DLX3 mutation (Q178R) transgene were 
purified and microinjected into C57BL/6 mouse oocytes, and the oocytes were surgically transferred to pseudo-
pregnant C57BL/6 mouse (Cyagen Biosciences Inc., Guangzhou, China). Initial genotyping of founder transgenic 
mice was performed by PCR using tail biopsies from pups. Positive founders for transgene were reconfirmed 
by western blot analysis to test the overexpression of DLX3. Transgenic mice were bred with wild type mice to 
generate (to obtain a defined genetic background) hemizygotes for the analysis of bone phenotype changes. In 
all experiments, female transgenic mice and female wild type littermates as controls were used. We established a 
sample of at least 5 mice per group.
Screening DLX3 status in BMSCs at DNA level. To screen DLX3 status in TDO- and CON-BMSCs, 
we collected cells from the patient and control donors at passage 1 and extracted DNA with the General 
AllGen Kit (Cwbiotech, Beijing, China) according to the manufacturer’s instruction. Exon 3 of DLX3 
was amplified using GoTaq Green Master Mix (Promega, Madison, WI) and exon 3 primer pair. The for-
ward exon 3 primer was 5′ -AGCATTCTGAGAGGCTAACTAGCTAC-3′ , and the reverse primer was 
5′ -AGGTTCTGTGCGTGATACCA-3′ . The PCR products were then sequenced on ABI 3730 sequencer.
Plasmids generation and cellular localization examination. To investigate the function of WT-DLX3 
and MT-DLX3 protein, GFP-tagged DLX3 fusion gene expression plasmids were constructed. Briefly, Human 
full-length DLX3 cDNA was synthesized and subcloned into pEGFP-C1 vector. The novel mutant cDLX3 
(c.533 A> G) and cDLX3 (c.571_574delGGGG) were generated from pEGFP-WT-DLX3 using single-site muta-
tion kit (Promega, Madison, WI). The sequences of WT-DLX3, MT-DLX3 and TR-DLX3 were confirmed by 
DNA sequencing. To investigate the cellular localization, different plasmids were respectively transfected into 
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MC3T3-E1 cells using Mirus TransIT-X2® Dynamic Delivery System following the manufacturer’s instruction. 
At 48 h post-transfection, the cellular localization of WT-DLX3, MT-DLX3 and TR-DLX3 was examined using 
an inverted fluorescence microscope.
Alkaline phosphatase (ALP) histochemistry and quantification of ALP activity. BMSCs were cultured 
in osteogenic medium for 3, 7, and 14 days. At the indicated times, the ALP histochemistry was stained with BCIP/
NBT solution (Cwbiotech) and ALP activity was measured with an ALP assay kit (Nanjing Jiancheng Bioengineering 
Institute, Nanjing, China) according to the manufacturer’s instruction. The details were described in supplementary.
Alizarin red staining and quantification of matrix mineralization. BMSCs were cultured in osteo-
genic medium for 14 and 21 days. At the indicated times, Alizarin red staining and quantification was performed. 
Details were described in supplementary.
Measurement of β-galactosidase activity and expression in BMSCs. Senescence-associated 
β -galactosidase (SA-β -gal) activity was assessed using two methods. Firstly, the same number (5 × 105) of BMSCs 
from both groups were seed into 60-mm culture dishes, and the medium was changed every 3 days. At 7 days 
post-inoculation, senescence was assessed using the senescence β -galactosidase staining kit (Beyotime Institute 
of Biotechnology, Jiangsu, China) according to the manufacturer’s instruction. To quantify SA-β -gal activity, we 
counted at least 300 cells in randomly choose fields and calculated the ratio of SA-β -gal+ cells to total cells. 
Secondly, to confirm the above result, BMSCs at passage 8 th were collected and analyzed by flow cytometry after 
incubation with anti-GLB1 antibody (Abcam, Cambridge, MA) and anti-human IgG isotype (GeneTex, Irvine, 
CA) for 1 h at 4 °C. The recommended PE-conjugated non-specific rabbit IgG [F(ab1)2 donkey anti-rabbit IgG PE 
secondary antibody (eBioscience, San Diego, CA)] was used as secondary antibody to measure GLB1 expression. 
Flow cytometry was performed on a Coulter Epics XL (Beckman Coulter, Inc.).
Electrophoretic mobility shift assay (EMSA). The nuclear extract (10 μ g of protein) was mixed with 
biotin-labeled DNA probe or cold competitor in binding buffer (LightShift® Chemiluminescent EMSA Kit). 
The reaction mixture was incubated for 30 min at room temperature. GFP antibody was included for supershift. 
Then, the reaction mixture was incubated for additional 30 min at room temperature. Samples were run on an 
acrylamide gel at 120 V for about 2 h. The gel was transferred to a nylon membrane. The biotin-labeled DNA was 
detected using the streptavidin-horseradish peroxidase conjugate and LightShift chemiluminescent substrate.
Telomere measurement by quantitative real-time PCR. Genome DNA was prepared using DNeasy 
Blood & Tissue Kit (Cwbiotech). Average telomere length was measured from total genomic DNA using a real-time 
PCR as previously described29,30. PCR reactions were performed on the ABI 7500 real-time PCR system (Life 
Technologies Corporation), using telomeric primers, primers for the reference control gene (human/mouse 36B4 
single copy gene). For each PCR reaction, a standard curve was made by serial dilutions of known amounts of DNA. 
The telomere signal was normalized to the signal from the single copy gene to generate a T/S ratio indicative of rela-
tive telomere length. For human absolute telomere length calculation, the telomere kb per reaction value was divided 
genome copy number (calculated from 36B4 Ct and standard curve) to generate a total telomeric length in kb per 
diploid genome49. Equal amounts of DNA (20 ng) were used for each reaction, with at least three replicates for each 
specimen. The telomere standard curve and 36B4 standard curve was supplied in Supplementary Fig. S6.
Real-time PCR analysis. Total RNA was isolated with TRIzol® reagent (Invitrogen Life Technologies) and 
2 μ g of RNA was reverse-transcribed into cDNA using the Superscript first-strand synthesis system (Invitrogen 
Life Technologies) according to protocol. Real-time PCR reactions were conducted in a 20-μ l reaction mixture 
(containing cDNA and SYBR green master mix) using an ABI 7500 real-time PCR system (Life Technologies 
Corporation). The mRNA expression relative to osteoclastogenesis was normalized to murine glyceralde-
hydephosphate dehydrogenase (GAPDH) and calculated using the 2−∆∆ Ct method. The sequences of each 
primer are listed in Supplementary Tables S1 and S2.
Western blot assay. Western blot assay was used to measure the protein expression, and the detailed proce-
dures were described as below. Cells were harvested and lysed in RIPA buffer containing protease inhibitors. After 
determining the concentration, protein samples were subjected to 10% sodium dodecyl sulfate polyacrylamide 
gel electrophoresis and transferred to a polyvinylidenedifluoride membrane. The membranes were blocked in 5% 
skim milk for 1 h and incubated with antibodies against RUNX2, BSP, RANKL, OPG (Santa Cruz Biotechnology, 
Santa Cruz, CA) human p16INK4a, OCN, OCT4, EGFP (Cell Signaling Technology, Beverly, MA), p16INK4a, GLB1, 
DLX3 (Abcam), β -actin and GAPDH (Proteintech, Chicago, IL) separately at 4 °C overnight. After incubation 
with peroxidase-linked secondary antibodies, immunoreactive proteins were visualized on an Odyssey infrared 
imaging system (Odyssey LI-COR Biosciences, Lincoln, NE).
Micro-CT analysis. Micro-CT analysis of specimens was performed using a high-resolution Inveon 
Micro-CT (Siemens, Munich, Germany). Briefly, the x-ray source was set at 60 kV, with a node current of 220 μ A 
and an exposure time of 400 ms for each of the 360 rotational steps. Image slices were then reconstructed using 
micro-CT image analysis software (Inveon Research Workplace). The regions of interest were defined as the areas 
between 0.5 mm and 1.0 mm proximal to the growth plate in the distal femurs, in order to include the secondary 
trabecular spongiosa. A threshold of 500 was used for evaluation of all scans. For visualization, we imported the 
segmented data and reconstructed them as a 3D-image displayed in micro-CT image analysis software (Inveon 
Research Workplace).
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Immunohistochemical analysis. The specimens were decalcified in 10% ethylene diamine tetraacetic acid 
(EDTA) for 1 month, and sectioned (5 μ m) for staining as previously described50. The specimens were incu-
bated with primary antibody against p16INK4a (Abcam) at 4 °C overnight. Then, samples were processed using the 
DAB detection kit (Zhangshanjinqiao, Beijing, China) and visualized under an Olympus BX51 light microscope 
equipped with an Olympus DP70 camera (Olympus, Co., Tokyo, Japan).
Statistical analysis. All data was representative of each assay repeated independently at least three times 
with similar results. Statistical significance was determined using the two-tailed Student’s t-test, assuming equal 
variances. The χ 2 test was used to compare rates. Significance is indicated as follows: *p < 0.05; **p < 0.01.
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